ScholarLens Back to search
2014•Unpublished venueRequires access

Diffuse Large B‐Cell Lymphoma

Andrew D. Zelenetz

Open publisher page 9 citations

Abstract

This chapter reviews the pathobiology of diffuse large B-cell lymphoma (DLBCL) as well as consideration regarding staging, management, and prognosis. It presents a series of multiple choice and discussion questions, and answers on the DLBCL. The chapter commences with a discourse on the expertise of a hematopathologist in the diagnosis of non-Hodgkin's lymphoma (NHL), and ends with the treatment of early-stage DLBCL. It also discusses on the role of the International Prognostic Index (IPI) model in the rituximab era, the data behind R-CHOP in DLBCL, and the approach in patients with hepatitis B virus (HBV) infection and DLBCL. In addition, the chapter tabulates the heterogeneity of the DLBCL.

About this research paper

What this paper is about

This chapter reviews the pathobiology of diffuse large B-cell lymphoma (DLBCL) as well as consideration regarding staging, management, and prognosis. It presents a series of multiple choice and discussion questions, and answers on the DLBCL. The chapter commences with a discourse on the expertise of a hematopathologist in the diagnosis of non-Hodgkin's lymphoma (NHL), and ends with the treatment of early-stage DLBCL. It also discusses on the role of the International Prognostic Index (IPI) model in the rituximab era, the data behind R-CHOP in DLBCL, and the approach in patients with hepatitis B virus (HBV) infection and DLBCL. In addition, the chapter tabulates the heterogeneity of the DLBCL.

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

This chapter reviews the pathobiology of diffuse large B-cell lymphoma (DLBCL) as well as consideration regarding staging, management, and prognosis. It presents a series of multiple choice and discussion questions, and answers on the DLBCL. The chapter commences with a discourse on the expertise of a hematopathologist in the diagnosis of non-Hodgkin's lymphoma (NHL), and ends with the treatment of early-stage DLBCL. It also discusses on the role of the International Prognostic Index (IPI) model in the rituximab era, the data behind R-CHOP in DLBCL, and the approach in patients with hepatitis B virus (HBV) infection and DLBCL. In addition, the chapter tabulates the heterogeneity of the DLBCL.

Key concepts: Diffuse large B-cell lymphoma, Rituximab, Lymphoma, International Prognostic Index, Medicine, CHOP, Hepatitis B virus, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Diffuse Large B‐Cell Lymphoma — Research Paper | ScholarLens